
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
pharmafile | May 14, 2019 | News story | Manufacturing and Production | Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy.
Regeneron chief scientific officer George Yancopoulos commented: “with today’s FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases.”
The approval was backed by data from the Phase 3 PANORAMA trial of 402 patients. The study found 80% of patients who received the drug every eight weeks experienced an at least 2-step improvement in the Diabetic Retinopathy Severity Scale score versus baseline, compared with 15 percent for placebo.
Eylea was first approved in the US for the treatment of wet age-related macular degeneration in 2011.
The drug is now being studied as a cancer treatment and being co-developed by Bayer and Regeneron for eye diseases.
Louis Goss
Related Content

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

Regeneron announces presentations of new data on Eylea HD for retinal disease
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data …




